viimane versioon :
22/08/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Ursodesoxycholique acid
keemiline struktuur
Viited : Ursodesoxycholique acid
tüüp
avaldamine
2410
ajaleht
Johnson CE, Streetman DD.
Stability of oral suspensions of ursodiol made from tablets
Am J Health-Syst Pharm 2002 ; 59: 361-363.
2449
ajaleht
Johnson CE, Nesbitt J.
Stability of ursodiol in an extemporaneously compounded oral liquid
Am J Health-Syst Pharm 1995 ; 52: 1798-1800.
3782
ajaleht
A. Santove?a, E. S?nchez-Negr?n, L. Charola, M. Llabr?s, J.B. Fari?a
Study of quality and stability of ursodeoxycholic acid formulations for oral pediatric administration
Int J Pharm 2014 , 477, 1-2 : 32-38.
4177
ajaleht
Polonini H, Loures da Silva S, Fernandes Brandao M.A, Bauters T, De Moerloose B, De Oliveira Ferreira A.
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF PH4.
Int J Pharm Compound 2018 ;22,6:516-526
4214
ajaleht
Pramar Y.V, Mandal T.K, Bostanian L.A, Nguyen A.TQ, Miller V, Morris T.C, Graves R.A.
Stability of Compounded Ursodiol Suspensions in PCCA Base, SuspendIt.
Int J Pharm Compound 2019 ;23,1:70-76
4498
ajaleht
Hausherr A, Roessle C, Pinet E, Vasseur V, Abarou T, Benakouche S, Bourdon O, Storme T.
Development and validation of a new HPLC method for the analysis of a novel oral suspension formulation of 50 mg/mL ursodesoxycholic acid for newborns.
Pharmaceutical Technology in Hospital Pharmacy 2020
Mentions Légales